News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cytyc Corporation (CYTC) Acquisition Of Proxima Therapeutics Clears Antitrust Review



10/19/2005 5:12:51 PM

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Feb. 24, 2005--Cytyc Corporation (Nasdaq: CYTC), a leading women's health company, today announced that it received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with Cytyc's acquisition of Proxima Therapeutics, Inc., a privately-held company that develops and markets innovative delivery systems for the treatment of cancer. Early termination of the Hart-Scott-Rodino waiting period satisfies one of the conditions necessary to complete the pending acquisition. The two companies announced on February 9, 2005, that they had entered into a definitive merger agreement for Cytyc to acquire Proxima for the purchase price of $160 million, plus a two-year earnout based on incremental sales growth in breast related products, to be paid out of existing cash. Proxima's lead product, the proprietary MammoSite(R) Radiation Therapy System, is a single-use device for the treatment of breast cancer that positions radiation sources directly into the post-lumpectomy site to optimize radiation treatment delivery while minimizing damage to healthy tissue.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES